[go: up one dir, main page]

MX2023010810A - Metodos mejorados para el uso de farmacos psicodelicos. - Google Patents

Metodos mejorados para el uso de farmacos psicodelicos.

Info

Publication number
MX2023010810A
MX2023010810A MX2023010810A MX2023010810A MX2023010810A MX 2023010810 A MX2023010810 A MX 2023010810A MX 2023010810 A MX2023010810 A MX 2023010810A MX 2023010810 A MX2023010810 A MX 2023010810A MX 2023010810 A MX2023010810 A MX 2023010810A
Authority
MX
Mexico
Prior art keywords
subject
improved methods
psychedelics
dissociative state
psilocin
Prior art date
Application number
MX2023010810A
Other languages
English (en)
Inventor
James Gilligan
Larry Norder
Original Assignee
Tryp Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tryp Therapeutics Inc filed Critical Tryp Therapeutics Inc
Publication of MX2023010810A publication Critical patent/MX2023010810A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
    • A61B5/165—Evaluating the state of mind, e.g. depression, anxiety
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316—Modalities, i.e. specific diagnostic methods
    • A61B5/369—Electroencephalography [EEG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Primary Health Care (AREA)
  • Developmental Disabilities (AREA)
  • Educational Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Social Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proporcionan métodos para tratar un trastorno psicológico en un sujeto, que comprenden administrar al sujeto una cantidad suficiente de psilocibina o psilocina para inducir un estado disociativo en el sujeto en menos de 30 minutos después de la administración; y mantener posteriormente la concentración media en plasma del fármaco psicodélico en un valor predeterminado para mantener el estado disociativo durante una ventana terapéutica.
MX2023010810A 2021-03-15 2022-03-15 Metodos mejorados para el uso de farmacos psicodelicos. MX2023010810A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163161070P 2021-03-15 2021-03-15
PCT/IB2022/052347 WO2022195489A2 (en) 2021-03-15 2022-03-15 Improved methods for the use of psychedelics

Publications (1)

Publication Number Publication Date
MX2023010810A true MX2023010810A (es) 2023-11-24

Family

ID=83321982

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010810A MX2023010810A (es) 2021-03-15 2022-03-15 Metodos mejorados para el uso de farmacos psicodelicos.

Country Status (8)

Country Link
US (2) US20240307420A1 (es)
EP (1) EP4308128A4 (es)
JP (1) JP2024510637A (es)
KR (1) KR20230165787A (es)
AU (1) AU2022239961B2 (es)
CA (1) CA3212065A1 (es)
MX (1) MX2023010810A (es)
WO (1) WO2022195489A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230277568A1 (en) * 2020-07-10 2023-09-07 Eleusis Therapeutics Us, Inc. Method of treatment for psilocybin or psilocin infusion
WO2022195489A2 (en) * 2021-03-15 2022-09-22 Tryp Therapeutics Inc. Improved methods for the use of psychedelics
EP4486448A1 (en) 2022-03-04 2025-01-08 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
WO2023220367A1 (en) * 2022-05-13 2023-11-16 Reset Pharmaceuticals, Inc. Administration of a psychedelic compound by intramuscular injection
EP4536238A1 (en) * 2022-06-08 2025-04-16 Tryp Therapeutics Inc. Treatment of binge eating disorder using psychedelics
US20240000795A1 (en) * 2022-06-30 2024-01-04 Terran Biosciences Inc. Methods and compositions relating to controlling psychedelic effects with serotonin receptor modulators
US12344583B2 (en) 2022-07-12 2025-07-01 Lobe Sciences Ltd. Solid psilocin salts
IL318233A (en) 2022-07-12 2025-03-01 Lobe Sciences Ltd Preparation of stable salts, esters and conjugates of psilocin and their uses
IT202200020892A1 (it) * 2022-10-11 2024-04-11 Sintalica S R L Composizione comprendente triptammina non fosforilata, antiossidante selezionato tra carotenoidi e integratori, e suoi usi farmaceutici
EP4601665A1 (en) * 2022-10-11 2025-08-20 Sintalica S.r.l. Composition comprising tryptamines and maois compounds selected from ?-carboline inhibitors, and pharmaceutical uses thereof
AU2023361184A1 (en) 2022-10-13 2025-04-24 Cybin Uk Ltd Method of administration of a parenteral formulation comprising a psychedelic agent
CN121038789A (zh) 2023-01-23 2025-11-28 赛本英国有限公司 通过肠胃外施用单一有效肠胃外剂量的短效致幻剂治疗精神或神经障碍
CN120916771A (zh) * 2023-02-10 2025-11-07 克力迈实验室公司 任选地与n-酰基乙醇胺组合地包含裸盖菇素的组合物及其用途
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
WO2025038542A1 (en) * 2023-08-11 2025-02-20 The Regents Of The University Of California Psilocybin for treating phantom pain
US20250177422A1 (en) * 2023-11-09 2025-06-05 Zylorion Health Inc. Co-administration of a co-crystal of psilocybin and psilocin with an atypical antipsychotic

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113993522A (zh) * 2019-04-17 2022-01-28 指南针探路者有限公司 用赛洛西宾治疗焦虑障碍、头痛病症和进食障碍的方法
US20210015738A1 (en) * 2019-07-17 2021-01-21 Concept Matrix Solutions Oral dissolvable film containing psychedelic compound
US11766445B2 (en) * 2019-07-18 2023-09-26 Concept Matrix Solutions Oral soft gel capsule containing psychedelic compound
US20230277568A1 (en) * 2020-07-10 2023-09-07 Eleusis Therapeutics Us, Inc. Method of treatment for psilocybin or psilocin infusion
WO2022195489A2 (en) * 2021-03-15 2022-09-22 Tryp Therapeutics Inc. Improved methods for the use of psychedelics

Also Published As

Publication number Publication date
US20240307420A1 (en) 2024-09-19
EP4308128A4 (en) 2025-02-19
CA3212065A1 (en) 2022-09-22
EP4308128A2 (en) 2024-01-24
JP2024510637A (ja) 2024-03-08
AU2022239961A1 (en) 2023-09-28
KR20230165787A (ko) 2023-12-05
WO2022195489A3 (en) 2022-10-20
US20250312364A1 (en) 2025-10-09
WO2022195489A2 (en) 2022-09-22
AU2022239961B2 (en) 2025-10-16

Similar Documents

Publication Publication Date Title
MX2023010810A (es) Metodos mejorados para el uso de farmacos psicodelicos.
Saijo et al. Lack of pain reduction by a vibrating local anesthetic attachment: a pilot study
IL134796A0 (en) Noribogaine in the treatment of pain and drug addiction
DK0723444T3 (da) Levobupivacain, som er egnet til behandling af kronisk smerte
ATE367816T1 (de) Verwendung von niedrigen dosen estrogen in kombination mit immunotherapeutischen verbindungen zur behandlung von immunkrankheiten
GR3034508T3 (en) Use of insulin sensitizing agents to treat hypertension.
MX2020002889A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y métodos de uso del mismo.
ZA202303456B (en) Use of benzodiazepines to increase sensitivity to psilocybin following a chronic ssri regimen
MY209349A (en) Methods of treating myeloproliferative disorders
NO20060913L (no) Behandling av avhengighetsabstinens
MX2022006566A (es) Tratamientos conjuntos para tratamiento de cancer de mama.
ATE536178T1 (de) Therapeutische anwendung von methionin zur behandlung oder prävention von mucositis
MX2023007413A (es) Metodos para monitorear digoxina con el uso de vibegron para tratar veiiga hiperactiva.
PH12015502465A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
ATE44156T1 (de) Kovalent gebundener heparin-antithrombin iiikomplex, verfahren zu dessen herstellung und seine verwendung zur behandlung von thrombusembolie.
ATE546136T1 (de) Kardioprotektions- und neuroprotektionsverfahren durch intravenöse verabreichung von halogenierten flüchtigen narkosemitteln
DE60030107D1 (de) Vitamin-d derivate zur behandlung des systemischen lupus erythematodes
MX2024002215A (es) Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada.
JPS56142213A (en) Pharmacuetical blend for treating parkinsonism syndrome
US6733748B2 (en) Chronic lymphocytic leukemia treatment
CL2024002662A1 (es) Métodos de tratamiento.
Shilo-Benjamini et al. Plasma bupivacaine concentrations following orbital injections in cats
PH12021551951A1 (en) Combination therapies for use in treating cancer
SE9101341D0 (sv) New medicinal use
Calvey et al. Kinetics of intravenous pyridostigmine in man